Surgit, OzgurPusuroglu, HamdiErturk, MehmetAkgul, OzgurButurak, AliAkkaya, EmreGul, MehmetUygur, BegumYazan, SerkanEksik, Abdurrahman2023-02-212023-02-212015-01-0110.5152/eurasianjmed.2015.43https://hdl.handle.net/11443/1394http://dx.doi.org/10.5152/eurasianjmed.2015.43Objective: Patients with resistant hypertension are at increased risk for cardiovascular events. Mean platelet volume (MPV) is an accepted biomarker of platelet activation and considered as a risk factor for cardiovascular disease. The aim of this study was to determine whether MPV levels are higher in resistant hypertensive (RHTN) patients than in controlled hypertensive (CHTN) patients and healthy normotensive controls. Materials and Methods: 279 consecutive patients were included in this study. Patients were divided into three groups: Resistant hypertension patient group {[}n=78mean age 56.8 +/- 9.842 males (53.8\%)]controlled hypertension patient group {[}n=121mean age 54.1 +/- 9.649 males (40.5\%)]and normotensive control group {[}n=80mean age 49.8 +/- 8.534 males (42.5\%)]. Physical examination, laboratory workup, and 24-hour ambulatory blood pressure measurement (ABPM) were performed in all participants. Results: The mean platelet volume levels were significantly higher in RHTN group than in the CHTN and normotensive groups (p<0.001). In correlation analysis office systolic and diastolic blood pressure was positively correlated with MPV. Conclusion: Our study demonstrated that MPV, as an important indicator of platelet activation, was statistically higher in RHTN patients than in CHTN and in normotensive subjects. Elevated MPV levels may help to determine a high risk group for atherosclerosis in RHTN patients.Mean platelet volumeresistant hypertensioncontrolled hypertensionArticleWOS:000360366100001